Isomorphic Labs partners with Merck on AI-designed cancer drug

demishassabis · x · 2026-11-21

Demis Hassabis announced a strategic research collaboration between Isomorphic Labs and MSD (Merck) to design a new cancer drug, combining Isomorphic's frontier AI drug-design capabilities with Merck's discovery, development and manufacturing expertise.

Isomorphic's modality-agnostic drug design engine (IsoDDE) is built on foundational AI models offering high predictive fidelity in novel biological systems. Hassabis called it another key proof point of the company's push to reimagine drug discovery.

Original post →

More from Companies & People

Companies & People channel →